Pharsight

Drugs that contain Naldemedine Tosylate

1. Symproic patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE46375 BDSI 6,7-unsaturated-7-carbamoyl substituted morphinan derivative
Oct, 2026

(2 years from now)

USRE46365 BDSI 6,7-unsaturated-7-carbamoyl substituted morphinan derivative
Jan, 2028

(3 years from now)

US9108975 BDSI Crystal of 6,7-unsaturated-7-carbamoyl morphinan derivative and method for producing the same
Nov, 2031

(7 years from now)

US10952968 BDSI Preparation containing 6,7-unsaturated-7-carbamoyl morphinan derivatives
May, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Mar 23, 2022

NCE-1 date: 2021-03-23

Market Authorisation Date: 23 March, 2017

Treatment: Treatment of opioid-induced constipation

Dosage: TABLET;ORAL

More Information on Dosage

SYMPROIC family patents

Family Patents